Open-market purchases of Fulcrum Therapeutics, Inc. (FULC) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Jul 21, 2026 | Kevin Tang10% Owner | $594K | Added | |||
| Jul 16: 116,671 shares @ $3.56 avg; Jul 17: 50,945 shares @ $3.52 avg. Indirect via Tang Capital Partners LP & affiliates. Post-purchase total: 7,080,945 shares. Prior tranche ~$891K filed Jul 15. Current price $3.62 (+2.3% from avg buy ~$3.54). | ||||||
| Jul 17, 2026 | Kevin Tang / Tang Capital Partners, L.P.10% Owner | $888K | Added | |||
| Open-market accumulation across July 13–15 at weighted avg ~$3.55/share. Tang Capital group total stake now 6,913,329 shares (~8.2%). Current price $3.50 (−1.4% from avg buy). FULC developing losmapimod for FSHD. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.